Tempus  

Tempus provides a comprehensive platform to support drug development across all lifecycle stages—from discovery to commercialization.

Multimodal Real-World Data: Access DNA, RNA, H&E images, and other clinical, imaging, and molecular data to uncover insights across the R&D continuum. Run custom analyses and surface insights quickly with Tempus Lens, and collaborate with experienced scientists to help achieve your research objectives. 

Biological Modeling: Leverage a robust library of patient-derived tumor organoids to generate multimodal insights—phenotypic, molecular, and clinical—and accelerate preclinical research.

Next-Generation Sequencing and CDx: Utilize a robust NGS portfolio including solid tissue, liquid biopsy, DNA, whole transcriptome RNA, treatment response monitoring, and MRD detection for research and CDx development.

Clinical Trial Solutions: Accelerate enrollment with AI-enabled patient matching across the Tempus TIME network, execute effective trials with our full-service CRO, Compass, and prospectively generate evidence with the Tempus Studies platform.

Care Gaps Closure: Tempus Next is designed to accelerate the adoption of evidence based care and increase adherence to clinical guidelines. Timely AI-enabled notifications help accelerate the adoption of precision care pathways and avoid gaps in care.

AI-Enabled Algorithms: Generate clinical insights without the need for an additional specimen through DNA, RNA, H&E image, or other health data. Leverage machine learning models to help discover, validate, and deploy algorithms to power your research. 

Tempus offers a broad range of molecular testing and AI-enabled technology solutions to help physicians make informed treatment decisions for patients across all stages of the cancer care continuum.

• One platform across the care continuum: A comprehensive platform that supports patients throughout their journey, offering tumor-naive and tumor-informed MRD assays for minimal residual disease and monitoring, alongside somatic and germline testing to provide valuable insights for individualized treatment plans and identification of hereditary risks.

• DNA + RNA sequencing: Solid tumor + normal match DNA sequencing helps provide true identification of somatic alterations, maximizing targeted therapy opportunities, while whole transcriptome RNA sequencing offers a deeper understanding of clinically actionable fusions and altered splicing.

• Solid tumor + liquid biopsy: Complimentary solid and liquid testing may maximize biomarker detection, identifying more clinically actionable variants linked to targeted therapy options.

• Tempus Hub & One: Streamline test ordering with one-click selection tailored to your patient’s cancer type, seamless order tracking, and a comprehensive patient timeline—providing key medical history, prior therapies, pathology, and radiology insights in one place. Integrated within Hub, Tempus One, an AI-enabled clinical assistant, delivers rapid access to critical patient insights.